1. Home
  2. TCI vs CLLS Comparison

TCI vs CLLS Comparison

Compare TCI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCI
  • CLLS
  • Stock Information
  • Founded
  • TCI 1983
  • CLLS 1999
  • Country
  • TCI United States
  • CLLS France
  • Employees
  • TCI N/A
  • CLLS N/A
  • Industry
  • TCI Real Estate
  • CLLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TCI Finance
  • CLLS Health Care
  • Exchange
  • TCI Nasdaq
  • CLLS Nasdaq
  • Market Cap
  • TCI 239.2M
  • CLLS 240.2M
  • IPO Year
  • TCI N/A
  • CLLS 2007
  • Fundamental
  • Price
  • TCI $27.50
  • CLLS $2.04
  • Analyst Decision
  • TCI
  • CLLS Buy
  • Analyst Count
  • TCI 0
  • CLLS 2
  • Target Price
  • TCI N/A
  • CLLS $8.00
  • AVG Volume (30 Days)
  • TCI 2.8K
  • CLLS 23.1K
  • Earning Date
  • TCI 11-07-2024
  • CLLS 11-04-2024
  • Dividend Yield
  • TCI N/A
  • CLLS N/A
  • EPS Growth
  • TCI N/A
  • CLLS N/A
  • EPS
  • TCI 0.69
  • CLLS N/A
  • Revenue
  • TCI $50,541,000.00
  • CLLS $19,635,000.00
  • Revenue This Year
  • TCI N/A
  • CLLS $271.02
  • Revenue Next Year
  • TCI N/A
  • CLLS $33.48
  • P/E Ratio
  • TCI $40.29
  • CLLS N/A
  • Revenue Growth
  • TCI N/A
  • CLLS N/A
  • 52 Week Low
  • TCI $26.91
  • CLLS $0.96
  • 52 Week High
  • TCI $43.40
  • CLLS $3.77
  • Technical
  • Relative Strength Index (RSI)
  • TCI 41.46
  • CLLS 44.35
  • Support Level
  • TCI $27.38
  • CLLS $1.95
  • Resistance Level
  • TCI $28.36
  • CLLS $2.06
  • Average True Range (ATR)
  • TCI 0.54
  • CLLS 0.10
  • MACD
  • TCI -0.05
  • CLLS -0.01
  • Stochastic Oscillator
  • TCI 31.05
  • CLLS 40.97

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Share on Social Networks: